Fate Therapeutics, Inc.
(NASDAQ : FATE)

( )
FATE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.14%151.410.0%$1218.22m
AMGNAmgen, Inc. 0.00%249.951.3%$706.86m
SNSSSunesis Pharmaceuticals, Inc. 0.00%8.000.7%$559.23m
NVAXNovavax, Inc. -0.67%193.3580.0%$536.05m
ILMNIllumina, Inc. 0.00%403.153.5%$527.32m
GILDGilead Sciences, Inc. -0.45%64.601.0%$470.31m
REGNRegeneron Pharmaceuticals, Inc. 0.62%480.002.7%$433.79m
VRTXVertex Pharmaceuticals, Inc. 0.07%216.101.9%$372.34m
ALXNAlexion Pharmaceuticals, Inc. 0.00%153.732.0%$315.33m
BIIBBiogen, Inc. 0.00%266.191.7%$292.97m
BNTXBioNTech SE -0.19%129.400.0%$218.39m
EXASEXACT Sciences Corp. 0.00%128.0018.4%$194.86m
NBIXNeurocrine Biosciences, Inc. 0.00%92.974.9%$172.50m
CRSPCRISPR Therapeutics AG 0.91%121.980.6%$170.89m
OCGNOcugen, Inc. 2.68%6.890.0%$150.48m

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.